Lung Cancer Vaccines and Therapeutic Antibodies: Pipeline, Strategies and Clinical - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

Lung Cancer Vaccines and Therapeutic Antibodies: Pipeline, Strategies and Clinical

Description:

Aarkstore.com announce a new report "Lung Cancer Vaccines and Therapeutic Antibodies: Pipeline, Strategies and Clinical" through its vast collection of market research report. – PowerPoint PPT presentation

Number of Views:193

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Lung Cancer Vaccines and Therapeutic Antibodies: Pipeline, Strategies and Clinical


1
Aarkstore.com Lung Cancer Vaccines and
Therapeutic Antibodies Pipeline, Strategies and
Clinical
2
Summary
  • This report provides a comprehensive review of 27
    candidate therapeutic antibodies and 42 candidate
    vaccines that are being evaluated for the
    treatment of lung cancer, covering pipeline,
    disease-targeting strategies and clinical
    findings. These antibodies are directed at 17
    targets, while the vaccines are directed at 24
    antigens or antigen combinations. Globally,
    lung cancer is the most common cancer and in 2008
    there were an estimated 1.6 million new cases and
    1.4 million deaths (almost 20 of all cancer
    deaths) caused by this disease. Five-year
    survival rates are also low (15-20) compared to
    other common cancers. In the US, studies have
    shown that lung cancer-care costs (in 2006) were
    the third highest of all cancers, while indirect
    costs (2005) were higher than for any other
    cancer. Patient needs and the high burden of
    lung cancer are driving the development of new
    therapies. While improvements have been seen in
    diagnosis and treatments (surgery, radiotherapy,
    chemotherapy and targeted drugs), new therapies
    that build on the capabilities of existing
    strategies, are urgently required. Today,
    advances continue to be made in drug treatments
    for lung cancer in chemotherapy, new drug
    combinations and targeted molecules. In
    particular, advances are being seen in the field
    of immunotherapy, in the development of new
    therapeutic antibodies and therapeutic vaccines.

3
Table of Contents
  • Summary1 Lung Cancer1.1 Statistics1.2
    Diagnosis1.3 Lung Cancer Staging1.4 Treatment
    of Lung Cancer1.5 Survival Rates1.6 Cost of
    Lung Cancer1.7 New Developments1.8 This
    ReportChapter 2 Approved and Late-Stage
    Therapeutic Antibodies (p.39) Summary2.1
    Introduction2.2 Overview2.3 (One antibody,
    Approved)2.4 2.6 (Three antibodies, Phase
    3)References

4
More Related Reports
  •   VEGF Inhibition Therapy-Indicating and
    Prognostic Biomarkers, 2011
  •   Biomarkers in Alzheimers Disease, 2011
  •   Alzheimers Disease Autoantibodies, Vaccines
    and Therapeutic Antibodies Pipeline, 2011
  •   Prostate Cancer Vaccines and Therapeutic
    Antibodies Pipeline, 2011
  •   Breast Cancer Vaccines and Therapeutic
    Antibodies Pipeline, 2011
  •   Alzheimers Disease Biomarkers in Cerebrospinal
    Fluid and Blood, 2011
  •   Image-Based Biomarkers in Alzheimers Disease,
    2011
  •   Lung Cancer Vaccines and Therapeutic
    Antibodies Pipeline, Strategies and Clinical

5
For More details
  • http//www.aarkstore.com/reports/Lung-Cancer-Vacci
    nes-and-Therapeutic-Antibodies-Pipeline-Strategies
    -and-Clinical-157138.html
  • Vina
  • Aarkstore.com
  • Contact Marketing team
  • Mob.No.918149852585
  • Email enquiry_at_aarkstore.com
  • URL http//www.aarkstore.com/
  • XML http//www.aarkstore.com/feeds/Biopharmrepor
    ts.xml
About PowerShow.com